Last reviewed · How we verify
SSRI monotherapy
At a glance
| Generic name | SSRI monotherapy |
|---|---|
| Also known as | SSRI |
| Sponsor | Inje University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (NA)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy (NA)
- Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (PHASE2)
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy (PHASE1)
- Psychoeducational Group for Depression (NA)
- Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder (PHASE4)
- Adding Exercise to Antidepressant Medication Treatment for Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |